Gastrointestinal Cancer

Yttrium-90 glass microspheres, a personalized radiotherapeutic cancer treatment, induced an overall response rate of 72.2% per blinded independent central review as neoadjuvant or stand-alone treatment in 143 evaluable patients with unresectable hepatocellular carcinoma.

Experts in CRC discuss questions and management of mCRC.

John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.

February 3, 2021 - The Drive-By Flu-Fecal Immunochemical Test program not only provides safe and socially distanced colorectal cancer screening opportunities during the coronavirus disease 2019 pandemic, but also may help to address screening declines in diverse communities.

Kohei Shitara, MD, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 in patients with metastatic gastric/gastroesophageal junction cancer.

February 2, 2021 - ASCO has chosen molecular profiling driving progress in gastointestinal cancers as its Advance of the Year.

Kristen K. Ciombor, MD, MSCI, discusses sequencing treatment options for patients with locally advanced rectal cancer.

Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.

Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.

John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.

Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.

BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.

Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.

January 28, 2021 - The anti–PD-1 antibody tislelizumab was found to significantly improve overall survival compared with investigator’s choice of chemotherapy in the treatment of patients with advanced, unresectable, or metastatic esophageal squamous cell carcinoma.

John L. Marshall, MD, discusses the emergence of novel HER2-targeted therapies for patients with colorectal cancer.

Kabir Mody, MD, discusses the unique approach used to deliver Y-90 glass microspheres to patients with unresectable hepatocellular carcinoma.

Ruth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.

January 27, 2021 - The FDA has granted an orphan drug designation to the small molecule chemotherapeutic uttroside-B for use as a treatment in patients with hepatocellular carcinoma.

January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

January 27, 2021 - Perioperative chemotherapy did not improve overall survival in patients with resectable pancreatic ductal adenocarcinoma when compared with historical data from adjuvant trials.

Kanwal Raghav, MBBS, MD, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer.

January 26, 2021 — Patients with colorectal cancer who had molecular residual disease positivity immediately after surgery were found to have a high risk of disease recurrence and longitudinal monitoring increased the predictive power of circulating tumor DNA.

Johanna C. Bendell, MD, moderates a peer exchange with fellow experts to discuss differences in germline and somatic BRCA mutations in pancreatic cancer, the role of molecular testing in hepatocellular carcinoma, and treatment options for patients with BRAF-mutant, microsatellite instability–high colorectal cancer.

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.